The Use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer

Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]

Siegel, R.L.; Miller, K.D.; Goding Sauer, A.; Fedewa, S.A.; Butterly, L.F.; Anderson, J.C.; Cercek, A.; Smith, R.A.; Jemal, A. Colorectal cancer statistics, 2020. CA Cancer J. Clin., 2020, 70(3), 145-164.
[http://dx.doi.org/10.3322/caac.21601] [PMID: 32133645]

Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73(1), 17-48.
[http://dx.doi.org/10.3322/caac.21763] [PMID: 36633525]

Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33.
[http://dx.doi.org/10.3322/caac.21708] [PMID: 35020204]

Miller, K.D.; Nogueira, L.; Devasia, T.; Mariotto, A.B.; Yabroff, K.R.; Jemal, A.; Kramer, J.; Siegel, R.L. Cancer treatment and survivorship statistics, 2022. CA Cancer J. Clin., 2022, 72(5), 409-436.
[http://dx.doi.org/10.3322/caac.21731] [PMID: 35736631]

Oncology, A.S.C. Colorectal Cancer. Statistics, 2022.

Oncology, E.S.f.M. FDA approves first non-invasive dna screening test for colorectal cancer. 2014. Available from: https://www.esmo.org/oncology-news/archive/fda-approves-first-non-invasive-dna-screening-test-for-colorectal-cancer#:~:text=The%20USA%20Food%20and%20Drug,colorectal%20cancer%20or%20its%20precursors.

García-Osogobio, S.M. Early detection of colorectal cancer. Endoscopy, 2013, 25, 88-91.

Diaz Tasende, J.; Marín Gabriel, J. Screening for colorectal cancer by fecal occult blood test. Rev. Esp. Enferm. Dig., 2008, 100, 315-319.
[PMID: 18752358]

Wang, J.; Li, S.; Liu, Y.; Zhang, C.; Li, H.; Lai, B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med., 2020, 9(1), 361-373.
[http://dx.doi.org/10.1002/cam4.2673] [PMID: 31693304]

Milette, S.; Sicklick, J.K.; Lowy, A.M.; Brodt, P. Molecular pathways: Targeting the microenvironment of liver metastases. Clin. Cancer Res., 2017, 23(21), 6390-6399.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1636] [PMID: 28615370]

Jin, K.; Gao, W.; Lu, Y.; Lan, H.; Teng, L.; Cao, F. Mechanisms regulating colorectal cancer cell metastasis into liver (Review). Oncol. Lett., 2012, 3(1), 11-15.
[http://dx.doi.org/10.3892/ol.2011.432] [PMID: 22740847]

Schirripa, M.; Lenz, H.J. Biomarker in colorectal cancer. Cancer J., 2016, 22(3), 156-164.
[http://dx.doi.org/10.1097/PPO.0000000000000190] [PMID: 27341592]

Dekker, E.; Tanis, P.J.; Vleugels, J.L.A.; Kasi, P.M.; Wallace, M.B. Colorectal cancer. Lancet, 2019, 394(10207), 1467-1480.
[http://dx.doi.org/10.1016/S0140-6736(19)32319-0] [PMID: 31631858]

Testa, U.; Pelosi, E.; Castelli, G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med. Sci. (Basel), 2018, 6(2), 31.
[http://dx.doi.org/10.3390/medsci6020031] [PMID: 29652830]

Siegel, R.L.; Fedewa, S.A.; Anderson, W.F.; Miller, K.D.; Ma, J.; Rosenberg, P.S.; Jemal, A. Colorectal cancer incidence patterns in the united states, 1974–2013. J. Natl. Cancer Inst., 2017, 109(8), djw322.
[http://dx.doi.org/10.1093/jnci/djw322] [PMID: 28376186]

Whiffin, N.; Hosking, F.J.; Farrington, S.M.; Palles, C.; Dobbins, S.E.; Zgaga, L.; Lloyd, A.; Kinnersley, B.; Gorman, M.; Tenesa, A.; Broderick, P.; Wang, Y.; Barclay, E.; Hayward, C.; Martin, L.; Buchanan, D.D.; Win, A.K.; Hopper, J.; Jenkins, M.; Lindor, N.M.; Newcomb, P.A.; Gallinger, S.; Conti, D.; Schumacher, F.; Casey, G.; Liu, T.; Campbell, H.; Lindblom, A.; Houlston, R.S.; Tomlinson, I.P.; Dunlop, M.G. Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. Hum. Mol. Genet., 2014, 23(17), 4729-4737.
[http://dx.doi.org/10.1093/hmg/ddu177] [PMID: 24737748]

Hawk, E.T.; Limburg, P.J.; Viner, J.L. Epidemiology and prevention of colorectal cancer. Surg. Clin. North Am., 2002, 82(5), 905-941.
[http://dx.doi.org/10.1016/S0039-6109(02)00046-4] [PMID: 12507200]

Fearon, E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol., 2011, 6(1), 479-507.
[http://dx.doi.org/10.1146/annurev-pathol-011110-130235] [PMID: 21090969]

Bower, J.J.; Vance, L.D.; Psioda, M.; Smith-Roe, S.L.; Simpson, D.A.; Ibrahim, J.G.; Hoadley, K.A.; Perou, C.M.; Kaufmann, W.K. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. NPJ Breast Cancer, 2017, 3(1), 9.
[http://dx.doi.org/10.1038/s41523-017-0009-7] [PMID: 28649649]

Taylor, D.P.; Burt, R.W.; Williams, M.S.; Haug, P.J.; Cannon-Albright, L.A. Population-based family history-specific risks for colorectal cancer: A constellation approach. Gastroenterology, 2010, 138(3), 877-885.
[http://dx.doi.org/10.1053/j.gastro.2009.11.044] [PMID: 19932107]

Rustgi, A.K. The genetics of hereditary colon cancer. Genes Dev., 2007, 21(20), 2525-2538.
[http://dx.doi.org/10.1101/gad.1593107] [PMID: 17938238]

Eaden, J.A.; Abrams, K.R.; Mayberry, J.F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut, 2001, 48(4), 526-535.
[http://dx.doi.org/10.1136/gut.48.4.526] [PMID: 11247898]

Gillespie, E.; Leeman, S.E.; Watts, L.A.; Coukos, J.A.; O’Brien, M.J.; Cerda, S.R.; Farraye, F.A.; Stucchi, A.F.; Becker, J.M. Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc. Natl. Acad. Sci., 2011, 108(42), 17420-17425.
[http://dx.doi.org/10.1073/pnas.1114275108] [PMID: 21969570]

Farraye, F.A.; Odze, R.D.; Eaden, J.; Itzkowitz, S.H.; McCabe, R.P.; Dassopoulos, T.; Lewis, J.D.; Ullman, T.A.; James, T., III; McLeod, R.; Burgart, L.J.; Allen, J.; Brill, J.V. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology, 2010, 138(2), 738-745.
[http://dx.doi.org/10.1053/j.gastro.2009.12.037] [PMID: 20141808]

Munkholm, P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2003, 18(Suppl. 2), 1-5.
[http://dx.doi.org/10.1046/j.1365-2036.18.s2.2.x] [PMID: 12950413]

Kim, E.R.; Chang, D.K. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J. Gastroenterol., 2014, 20(29), 9872-9881.
[http://dx.doi.org/10.3748/wjg.v20.i29.9872] [PMID: 25110418]

Isidro, R.A.; Cruz, M.L.; Isidro, A.A.; Baez, A.; Arroyo, A.; González-Marqués, W.A.; González-Keelan, C.; Torres, E.A.; Appleyard, C.B. Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia. World J. Gastroenterol., 2015, 21(6), 1749-1758.
[http://dx.doi.org/10.3748/wjg.v21.i6.1749] [PMID: 25684939]

Nojadeh, J.N.; Behrouz Sharif, S.; Sakhinia, E. Microsatellite instability in colorectal cancer. EXCLI J., 2018, 17, 159-168.
[http://dx.doi.org/10.17179/excli2017-948] [PMID: 29743854]

Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol., 2006, 7(5), 335-346.
[http://dx.doi.org/10.1038/nrm1907] [PMID: 16612326]

Malki, A.; ElRuz, R.A.; Gupta, I.; Allouch, A.; Vranic, S.; Al Moustafa, A.E. Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements. Int. J. Mol. Sci., 2020, 22(1), 130.
[http://dx.doi.org/10.3390/ijms22010130] [PMID: 33374459]

Poynter, J.N.; Siegmund, K.D.; Weisenberger, D.J.; Long, T.I.; Thibodeau, S.N.; Lindor, N.; Young, J.; Jenkins, M.A.; Hopper, J.L.; Baron, J.A.; Buchanan, D.; Casey, G.; Levine, A.J.; Marchand, L.L.; Gallinger, S.; Bapat, B.; Potter, J.D.; Newcomb, P.A.; Haile, R.W.; Laird, P.W. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol. Biomarkers Prev., 2008, 17(11), 3208-3215.
[http://dx.doi.org/10.1158/1055-9965.EPI-08-0512] [PMID: 18990764]

Battaglin, F.; Naseem, M.; Lenz, H.J.; Salem, M.E. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin. Adv. Hematol. Oncol., 2018, 16(11), 735-745.
[PMID: 30543589]

Sahin, I.H.; Ciombor, K.K.; Diaz, L.A.; Yu, J.; Kim, R. Immunotherapy for microsatellite stable colorectal cancers: Challenges and novel therapeutic avenues. Am. Soc. Clin. Oncol. Educ. Book, 2022, 42(42), 242-253.
[http://dx.doi.org/10.1200/EDBK_349811] [PMID: 35658496]

Poulogiannis, G.; Ichimura, K.; Hamoudi, R.A.; Luo, F.; Leung, S.Y.; Yuen, S.T.; Harrison, D.J.; Wyllie, A.H.; Arends, M.J. Prognostic relevance of DNA copy number changes in colorectal cancer. J. Pathol., 2010, 220(3), 338-347.
[http://dx.doi.org/10.1002/path.2640] [PMID: 19911421]

Silva, A.L.; Dawson, S.N.; Arends, M.J.; Guttula, K.; Hall, N.; Cameron, E.A.; Huang, T.H.M.; Brenton, J.D.; Tavaré, S.; Bienz, M.; Ibrahim, A.E.K. Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer, 2014, 14(1), 891.
[http://dx.doi.org/10.1186/1471-2407-14-891] [PMID: 25432628]

Fodde, R. The APC gene in colorectal cancer. Eur. J. Cancer, 2002, 38(7), 867-871.
[http://dx.doi.org/10.1016/S0959-8049(02)00040-0] [PMID: 11978510]

Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 1990, 61(5), 759-767.
[http://dx.doi.org/10.1016/0092-8674(90)90186-I] [PMID: 2188735]

Bienz, M.; Clevers, H. Linking colorectal cancer to Wnt signaling. Cell, 2000, 103(2), 311-320.
[http://dx.doi.org/10.1016/S0092-8674(00)00122-7] [PMID: 11057903]

Müller, M.F.; Ibrahim, A.E.K.; Arends, M.J. Molecular pathological classification of colorectal cancer. Virchows Arch., 2016, 469(2), 125-134.
[http://dx.doi.org/10.1007/s00428-016-1956-3] [PMID: 27325016]

Liao, W.; Overman, M.J.; Boutin, A.T.; Shang, X.; Zhao, D.; Dey, P.; Li, J.; Wang, G.; Lan, Z.; Li, J.; Tang, M.; Jiang, S.; Ma, X.; Chen, P.; Katkhuda, R.; Korphaisarn, K.; Chakravarti, D.; Chang, A.; Spring, D.J.; Chang, Q.; Zhang, J.; Maru, D.M.; Maeda, D.Y.; Zebala, J.A.; Kopetz, S.; Wang, Y.A.; DePinho, R.A. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell, 2019, 35(4), 559-572.e7.
[http://dx.doi.org/10.1016/j.ccell.2019.02.008] [PMID: 30905761]

de Sánchez, M.T.G. Cáncer colorrectal (CCR). Rev. Colomb. Gastroenterol., 2005, 20, 43-53.

Gerstung, M.; Jolly, C.; Leshchiner, I.; Dentro, S.C.; Gonzalez, S.; Rosebrock, D.; Mitchell, T.J.; Rubanova, Y.; Anur, P.; Yu, K.; Tarabichi, M.; Deshwar, A.; Wintersinger, J.; Kleinheinz, K.; Vázquez-García, I.; Haase, K.; Jerman, L.; Sengupta, S.; Macintyre, G.; Malikic, S.; Donmez, N.; Livitz, D.G.; Cmero, M.; Demeulemeester, J.; Schumacher, S.; Fan, Y.; Yao, X.; Lee, J.; Schlesner, M.; Boutros, P.C.; Bowtell, D.D.; Zhu, H.; Getz, G.; Imielinski, M.; Beroukhim, R.; Sahinalp, S.C.; Ji, Y.; Peifer, M.; Markowetz, F.; Mustonen, V.; Yuan, K.; Wang, W.; Morris, Q.D.; Dentro, S.C.; Leshchiner, I.; Gerstung, M.; Jolly, C.; Haase, K.; Tarabichi, M.; Wintersinger, J.; Deshwar, A.G.; Yu, K.; Gonzalez, S.; Rubanova, Y.; Macintyre, G.; Adams, D.J.; Anur, P.; Beroukhim, R.; Boutros, P.C.; Bowtell, D.D.; Campbell, P.J.; Cao, S.; Christie, E.L.; Cmero, M.; Cun, Y.; Dawson, K.J.; Demeulemeester, J.; Donmez, N.; Drews, R.M.; Eils, R.; Fan, Y.; Fittall, M.; Garsed, D.W.; Getz, G.; Ha, G.; Imielinski, M.; Jerman, L.; Ji, Y.; Kleinheinz, K.; Lee, J.; Lee-Six, H.; Livitz, D.G.; Malikic, S.; Markowetz, F.; Martincorena, I.; Mitchell, T.J.; Mustonen, V.; Oesper, L.; Peifer, M.; Peto, M.; Raphael, B.J.; Rosebrock, D.; Sahinalp, S.C.; Salcedo, A.; Schlesner, M.; Schumacher, S.; Sengupta, S.; Shi, R.; Shin, S.J.; Spiro, O.; Stein, L.D.; Vázquez-García, I.; Vembu, S.; Wheeler, D.A.; Yang, T-P.; Yao, X.; Yuan, K.; Zhu, H.; Wang, W.; Morris, Q.D.; Spellman, P.T.; Wedge, D.C.; Van Loo, P.; Spellman, P.T.; Wedge, D.C.; Van Loo, P.; Aaltonen, L.A.; Abascal, F.; Abeshouse, A.; Aburatani, H.; Adams, D.J.; Agrawal, N.; Ahn, K.S.; Ahn, S-M.; Aikata, H.; Akbani, R.; Akdemir, K.C.; Al-Ahmadie, H.; Al-Sedairy, S.T.; Al-Shahrour, F.; Alawi, M.; Albert, M.; Aldape, K.; Alexandrov, L.B.; Ally, A.; Alsop, K.; Alvarez, E.G.; Amary, F.; Amin, S.B.; Aminou, B.; Ammerpohl, O.; Anderson, M.J.; Ang, Y.; Antonello, D.; Anur, P.; Aparicio, S.; Appelbaum, E.L.; Arai, Y.; Aretz, A.; Arihiro, K.; Ariizumi, S.; Armenia, J.; Arnould, L.; Asa, S.; Assenov, Y.; Atwal, G.; Aukema, S.; Auman, J.T.; Aure, M.R.R.; Awadalla, P.; Aymerich, M.; Bader, G.D.; Baez-Ortega, A.; Bailey, M.H.; Bailey, P.J.; Balasundaram, M.; Balu, S.; Bandopadhayay, P.; Banks, R.E.; Barbi, S.; Barbour, A.P.; Barenboim, J.; Barnholtz-Sloan, J.; Barr, H.; Barrera, E.; Bartlett, J.; Bartolome, J.; Bassi, C.; Bathe, O.F.; Baumhoer, D.; Bavi, P.; Baylin, S.B.; Bazant, W.; Beardsmore, D.; Beck, T.A.; Behjati, S.; Behren, A.; Niu, B.; Bell, C.; Beltran, S.; Benz, C.; Berchuck, A.; Bergmann, A.K.; Bergstrom, E.N.; Berman, B.P.; Berney, D.M.; Bernhart, S.H.; Beroukhim, R.; Berrios, M.; Bersani, S.; Bertl, J.; Betancourt, M.; Bhandari, V.; Bhosle, S.G.; Biankin, A.V.; Bieg, M.; Bigner, D.; Binder, H.; Birney, E.; Birrer, M.; Biswas, N.K.; Bjerkehagen, B.; Bodenheimer, T.; Boice, L.; Bonizzato, G.; De Bono, J.S.; Boot, A.; Bootwalla, M.S.; Borg, A.; Borkhardt, A.; Boroevich, K.A.; Borozan, I.; Borst, C.; Bosenberg, M.; Bosio, M.; Boultwood, J.; Bourque, G.; Boutros, P.C.; Bova, G.S.; Bowen, D.T.; Bowlby, R.; Bowtell, D.D.L.; Boyault, S.; Boyce, R.; Boyd, J.; Brazma, A.; Brennan, P.; Brewer, D.S.; Brinkman, A.B.; Bristow, R.G.; Broaddus, R.R.; Brock, J.E.; Brock, M.; Broeks, A.; Brooks, A.N.; Brooks, D.; Brors, B.; Brunak, S.; Bruxner, T.J.C.; Bruzos, A.L.; Buchanan, A.; Buchhalter, I.; Buchholz, C.; Bullman, S.; Burke, H.; Burkhardt, B.; Burns, K.H.; Busanovich, J.; Bustamante, C.D.; Butler, A.P.; Butte, A.J.; Byrne, N.J.; Børresen-Dale, A-L.; Caesar-Johnson, S.J.; Cafferkey, A.; Cahill, D.; Calabrese, C.; Caldas, C.; Calvo, F.; Camacho, N.; Campbell, P.J.; Campo, E.; Cantù, C.; Cao, S.; Carey, T.E.; Carlevaro-Fita, J.; Carlsen, R.; Cataldo, I.; Cazzola, M.; Cebon, J.; Cerfolio, R.; Chadwick, D.E.; Chakravarty, D.; Chalmers, D.; Chan, C.W.Y.; Chan, K.; Chan-Seng-Yue, M.; Chandan, V.S.; Chang, D.K.; Chanock, S.J.; Chantrill, L.A.; Chateigner, A.; Chatterjee, N.; Chayama, K.; Chen, H-W.; Chen, J.; Chen, K.; Chen, Y.; Chen, Z.; Cherniack, A.D.; Chien, J.; Chiew, Y-E.; Chin, S-F.; Cho, J.; Cho, S.; Choi, J.K.; Choi, W.; Chomienne, C.; Chong, Z.; Choo, S.P.; Chou, A.; Christ, A.N.; Christie, E.L.; Chuah, E.; Cibulskis, C.; Cibulskis, K.; Cingarlini, S.; Clapham, P.; Claviez, A.; Cleary, S.; Cloonan, N.; Cmero, M.; Collins, C.C.; Connor, A.A.; Cooke, S.L.; Cooper, C.S.; Cope, L.; Corbo, V.; Cordes, M.G.; Cordner, S.M.; Cortés-Ciriano, I.; Covington, K.; Cowin, P.A.; Craft, B.; Craft, D.; Creighton, C.J.; Cun, Y.; Curley, E.; Cutcutache, I.; Czajka, K.; Czerniak, B.; Dagg, R.A.; Danilova, L.; Davi, M.V.; Davidson, N.R.; Davies, H.; Davis, I.J.; Davis-Dusenbery, B.N.; Dawson, K.J.; De La Vega, F.M.; De Paoli-Iseppi, R.; Defreitas, T.; Tos, A.P.D.; Delaneau, O.; Demchok, J.A.; Demeulemeester, J.; Demidov, G.M.; Demircioğlu, D.; Dennis, N.M.; Denroche, R.E.; Dentro, S.C.; Desai, N.; Deshpande, V.; Deshwar, A.G.; Desmedt, C.; Deu-Pons, J.; Dhalla, N.; Dhani, N.C.; Dhingra, P.; Dhir, R.; DiBiase, A.; Diamanti, K.; Ding, L.; Ding, S.; Dinh, H.Q.; Dirix, L.; Doddapaneni, H.V.; Donmez, N.; Dow, M.T.; Drapkin, R.; Drechsel, O.; Drews, R.M.; Serge, S.; Dudderidge, T.; Dueso-Barroso, A.; Dunford, A.J.; Dunn, M.; Dursi, L.J.; Duthie, F.R.; Dutton-Regester, K.; Eagles, J.; Easton, D.F.; Edmonds, S.; Edwards, P.A.; Edwards, S.E.; Eeles, R.A.; Ehinger, A.; Eils, J.; Eils, R.; El-Naggar, A.; Eldridge, M.; Ellrott, K.; Erkek, S.; Escaramis, G.; Espiritu, S.M.G.; Estivill, X.; Etemadmoghadam, D.; Eyfjord, J.E.; Faltas, B.M.; Fan, D.; Fan, Y.; Faquin, W.C.; Farcas, C.; Fassan, M.; Fatima, A.; Favero, F.; Fayzullaev, N.; Felau, I.; Fereday, S.; Ferguson, M.L.; Ferretti, V.; Feuerbach, L.; Field, M.A.; Fink, J.L.; Finocchiaro, G.; Fisher, C.; Fittall, M.W.; Fitzgerald, A.; Fitzgerald, R.C.; Flanagan, A.M.; Fleshner, N.E.; Flicek, P.; Foekens, J.A.; Fong, K.M.; Fonseca, N.A.; Foster, C.S.; Fox, N.S.; Fraser, M.; Frazer, S.; Frenkel-Morgenstern, M.; Friedman, W.; Frigola, J.; Fronick, C.C.; Fujimoto, A.; Fujita, M.; Fukayama, M.; Fulton, L.A.; Fulton, R.S.; Furuta, M.; Futreal, P.A.; Füllgrabe, A.; Gabriel, S.B.; Gallinger, S.; Gambacorti-Passerini, C.; Gao, J.; Gao, S.; Garraway, L.; Garred, Ø.; Garrison, E.; Garsed, D.W.; Gehlenborg, N.; Gelpi, J.L.L.; George, J.; Gerhard, D.S.; Gerhauser, C.; Gershenwald, J.E.; Gerstein, M.; Gerstung, M.; Getz, G.; Ghori, M.; Ghossein, R.; Giama, N.H.; Gibbs, R.A.; Gibson, B.; Gill, A.J.; Gill, P.; Giri, D.D.; Glodzik, D.; Gnanapragasam, V.J.; Goebler, M.E.; Goldman, M.J.; Gomez, C.; Gonzalez, S.; Gonzalez-Perez, A.; Gordenin, D.A.; Gossage, J.; Gotoh, K.; Govindan, R.; Grabau, D.; Graham, J.S.; Grant, R.C.; Green, A.R.; Green, E.; Greger, L.; Grehan, N.; Grimaldi, S.; Grimmond, S.M.; Grossman, R.L.; Grundhoff, A.; Gundem, G.; Guo, Q.; Gupta, M.; Gupta, S.; Gut, I.G.; Gut, M.; Göke, J.; Ha, G.; Haake, A.; Haan, D.; Haas, S.; Haase, K.; Haber, J.E.; Habermann, N.; Hach, F.; Haider, S.; Hama, N.; Hamdy, F.C.; Hamilton, A.; Hamilton, M.P.; Han, L.; Hanna, G.B.; Hansmann, M.; Haradhvala, N.J.; Harismendy, O.; Harliwong, I.; Harmanci, A.O.; Harrington, E.; Hasegawa, T.; Haussler, D.; Hawkins, S.; Hayami, S.; Hayashi, S.; Hayes, D.N.; Hayes, S.J.; Hayward, N.K.; Hazell, S.; He, Y.; Heath, A.P.; Heath, S.C.; Hedley, D.; Hegde, A.M.; Heiman, D.I.; Heinold, M.C.; Heins, Z.; Heisler, L.E.; Hellstrom-Lindberg, E.; Helmy, M.; Heo, S.G.; Hepperla, A.J.; Heredia-Genestar, J.M.; Herrmann, C.; Hersey, P.; Hess, J.M.; Hilmarsdottir, H.; Hinton, J.; Hirano, S.; Hiraoka, N.; Hoadley, K.A.; Hobolth, A.; Hodzic, E.; Hoell, J.I.; Hoffmann, S.; Hofmann, O.; Holbrook, A.; Holik, A.Z.; Hollingsworth, M.A.; Holmes, O.; Holt, R.A.; Hong, C.; Hong, E.P.; Hong, J.H.; Hooijer, G.K.; Hornshøj, H.; Hosoda, F.; Hou, Y.; Hovestadt, V.; Howat, W.; Hoyle, A.P.; Hruban, R.H.; Hu, J.; Hu, T.; Hua, X.; Huang, K.; Huang, M.; Huang, M.N.; Huang, V.; Huang, Y.; Huber, W.; Hudson, T.J.; Hummel, M.; Hung, J.A.; Huntsman, D.; Hupp, T.R.; Huse, J.; Huska, M.R.; Hutter, B.; Hutter, C.M.; Hübschmann, D.; Iacobuzio-Donahue, C.A.; Imbusch, C.D.; Imielinski, M.; Imoto, S.; Isaacs, W.B.; Isaev, K.; Ishikawa, S.; Iskar, M.; Islam, S.M.A.; Ittmann, M.; Ivkovic, S.; Izarzugaza, J.M.G.; Jacquemier, J.; Jakrot, V.; Jamieson, N.B.; Jang, G.H.; Jang, S.J.; Jayaseelan, J.C.; Jayasinghe, R.; Jefferys, S.R.; Jegalian, K.; Jennings, J.L.; Jeon, S-H.; Jerman, L.; Ji, Y.; Jiao, W.; Johansson, P.A.; Johns, A.L.; Johns, J.; Johnson, R.; Johnson, T.A.; Jolly, C.; Joly, Y.; Jonasson, J.G.; Jones, C.D.; Jones, D.R.; Jones, D.T.W.; Jones, N.; Jones, S.J.M.; Jonkers, J.; Ju, Y.S.; Juhl, H.; Jung, J.; Juul, M.; Juul, R.I.; Juul, S.; Jäger, N.; Kabbe, R.; Kahles, A.; Kahraman, A.; Kaiser, V.B.; Kakavand, H.; Kalimuthu, S.; von Kalle, C.; Kang, K.J.; Karaszi, K.; Karlan, B.; Karlić, R.; Karsch, D.; Kasaian, K.; Kassahn, K.S.; Katai, H.; Kato, M.; Katoh, H.; Kawakami, Y.; Kay, J.D.; Kazakoff, S.H.; Kazanov, M.D.; Keays, M.; Kebebew, E.; Kefford, R.F.; Kellis, M.; Kench, J.G.; Kennedy, C.J.; Kerssemakers, J.N.A.; Khoo, D.; Khoo, V.; Khuntikeo, N.; Khurana, E.; Kilpinen, H.; Kim, H.K.; Kim, H-L.; Kim, H-Y.; Kim, H.; Kim, J.; Kim, J.; Kim, J.K.; Kim, Y.; King, T.A.; Klapper, W.; Kleinheinz, K.; Klimczak, L.J.; Knappskog, S.; Kneba, M.; Knoppers, B.M.; Koh, Y.; Komorowski, J.; Komura, D.; Komura, M.; Kong, G.; Kool, M.; Korbel, J.O.; Korchina, V.; Korshunov, A.; Koscher, M.; Koster, R.; Kote-Jarai, Z.; Koures, A.; Kovacevic, M.; Kremeyer, B.; Kretzmer, H.; Kreuz, M.; Krishnamurthy, S.; Kube, D.; Kumar, K.; Kumar, P.; Kumar, S.; Kumar, Y.; Kundra, R.; Kübler, K.; Küppers, R.; Lagergren, J.; Lai, P.H.; Laird, P.W.; Lakhani, S.R.; Lalansingh, C.M.; Lalonde, E.; Lamaze, F.C.; Lambert, A.; Lander, E.; Landgraf, P.; Landoni, L.; Langerød, A.; Lanzós, A.; Larsimont, D.; Larsson, E.; Lathrop, M.; Lau, L.M.S.; Lawerenz, C.; Lawlor, R.T.; Lawrence, M.S.; Lazar, A.J.; Lazic, A.M.; Le, X.; Lee, D.; Lee, D.; Lee, E.A.; Lee, H.J.; Lee, J.J-K.; Lee, J-Y.; Lee, J.; Lee, M.T.M.; Lee-Six, H.; Lehmann, K-V.; Lehrach, H.; Lenze, D.; Leonard, C.R.; Leongamornlert, D.A.; Leshchiner, I.; Letourneau, L.; Letunic, I.; Levine, D.A.; Lewis, L.; Ley, T.; Li, C.; Li, C.H.; Li, H.I.; Li, J.; Li, L.; Li, S.; Li, S.; Li, X.; Li, X.; Li, X.; Li, Y.; Liang, H.; Liang, S-B.; Lichter, P.; Lin, P.; Lin, Z.; Linehan, W.M.; Lingjærde, O.C.; Liu, D.; Liu, E.M.; Liu, F-F.F.; Liu, F.; Liu, J.; Liu, X.; Livingstone, J.; Livitz, D.; Livni, N.; Lochovsky, L.; Loeffler, M.; Long, G.V.; Lopez-Guillermo, A.; Lou, S.; Louis, D.N.; Lovat, L.B.; Lu, Y.; Lu, Y-J.; Lu, Y.; Luchini, C.; Lungu, I.; Luo, X.; Luxton, H.J.; Lynch, A.G.; Lype, L.; López, C.; López-Otín, C.; Ma, E.Z.; Ma, Y.; MacGrogan, G.; MacRae, S.; Macintyre, G.; Madsen, T.; Maejima, K.; Mafficini, A.; Maglinte, D.T.; Maitra, A.; Majumder, P.P.; Malcovati, L.; Malikic, S.; Malleo, G.; Mann, G.J.; Mantovani-Löffler, L.; Marchal, K.; Marchegiani, G.; Mardis, E.R.; Margolin, A.A.; Marin, M.G.; Markowetz, F.; Markowski, J.; Marks, J.; Marques-Bonet, T.; Marra, M.A.; Marsden, L.; Martens, J.W.M.; Martin, S.; Martin-Subero, J.I.; Martincorena, I.; Martinez- Fundichely, A.; Maruvka, Y.E.; Mashl, R.J.; Massie, C.E.; Matthew, T.J.; Matthews, L.; Mayer, E.; Mayes, S.; Mayo, M.; Mbabaali, F.; McCune, K.; McDermott, U.; McGillivray, P.D.; McLellan, M.D.; McPherson, J.D.; McPherson, J.R.; McPherson, T.A.; Meier, S.R.; Meng, A.; Meng, S.; Menzies, A.; Merrett, N.D.; Merson, S.; Meyerson, M.; Meyerson, W.; Mieczkowski, P.A.; Mihaiescu, G.L.; Mijalkovic, S.; Mikkelsen, T.; Milella, M.; Mileshkin, L.; Miller, C.A.; Miller, D.K.; Miller, J.K.; Mills, G.B.; Milovanovic, A.; Minner, S.; Miotto, M.; Arnau, G.M.; Mirabello, L.; Mitchell, C.; Mitchell, T.J.; Miyano, S.; Miyoshi, N.; Mizuno, S.; Molnár-Gábor, F.; Moore, M.J.; Moore, R.A.; Morganella, S.; Morris, Q.D.; Morrison, C.; Mose, L.E.; Moser, C.D.; Muiños, F.; Mularoni, L.; Mungall, A.J.; Mungall, K.; Musgrove, E.A.; Mustonen, V.; Mutch, D.; Muyas, F.; Muzny, D.M.; Muñoz, A.; Myers, J.; Myklebost, O.; Möller, P.; Nagae, G.; Nagrial, A.M.; Nahal- Bose, H.K.; Nakagama, H.; Nakagawa, H.; Nakamura, H.; Nakamura, T.; Nakano, K.; Nandi, T.; Nangalia, J.; Nastic, M.; Navarro, A.; Navarro, F.C.P.; Neal, D.E.; Nettekoven, G.; Newell, F.; Newhouse, S.J.; Newton, Y.; Ng, A.W.T.; Ng, A.; Nicholson, J.; Nicol, D.; Nie, Y.; Nielsen, G.P.; Nielsen, M.M.; Nik-Zainal, S.; Noble, M.S.; Nones, K.; Northcott, P.A.; Notta, F.; O’Connor, B.D.; O’Donnell, P.; O’Donovan, M.; O’Meara, S.; O’Neill, B.P.; O’Neill, J.R.; Ocana, D.; Ochoa, A.; Oesper, L.; Ogden, C.; Ohdan, H.; Ohi, K.; Ohno-Machado, L.; Oien, K.A.; Ojesina, A.I.; Ojima, H.; Okusaka, T.; Omberg, L.; Ong, C.K.; Ossowski, S.; Ott, G.; Ouellette, B.F.F.; P’ng, C.; Paczkowska, M.; Paiella, S.; Pairojkul, C.; Pajic, M.; Pan-Hammarström, Q.; Papaemmanuil, E.; Papatheodorou, I.; Paramasivam, N.; Park, J.W.; Park, J-W.; Park, K.; Park, K.; Park, P.J.; Parker, J.S.; Parsons, S.L.; Pass, H.; Pasternack, D.; Pastore, A.; Patch, A-M.; Pauporté, I.; Pea, A.; Pearson, J.V.; Pedamallu, C.S.; Pedersen, J.S.; Pederzoli, P.; Peifer, M.; Pennell, N.A.; Perou, C.M.; Perry, M.D.; Petersen, G.M.; Peto, M.; Petrelli, N.; Petryszak, R.; Pfister, S.M.; Phillips, M.; Pich, O.; Pickett, H.A.; Pihl, T.D.; Pillay, N.; Pinder, S.; Pinese, M.; Pinho, A.V.; Pitkänen, E.; Pivot, X.; Piñeiro-Yáñez, E.; Planko, L.; Plass, C.; Polak, P.; Pons, T.; Popescu, I.; Potapova, O.; Prasad, A.; Preston, S.R.; Prinz, M.; Pritchard, A.L.; Prokopec, S.D.; Provenzano, E.; Puente, X.S.; Puig, S.; Puiggròs, M.; Pulido-Tamayo, S.; Pupo, G.M.; Purdie, C.A.; Quinn, M.C.; Rabionet, R.; Rader, J.S.; Radlwimmer, B.; Radovic, P.; Raeder, B.; Raine, K.M.; Ramakrishna, M.; Ramakrishnan, K.; Ramalingam, S.; Raphael, B.J.; Rathmell, W.K.; Rausch, T.; Reifenberger, G.; Reimand, J.; Reis-Filho, J.; Reuter, V.; Reyes-Salazar, I.; Reyna, M.A.; Reynolds, S.M.; Rheinbay, E.; Riazalhosseini, Y.; Richardson, A.L.; Richter, J.; Ringel, M.; Ringnér, M.; Rino, Y.; Rippe, K.; Roach, J.; Roberts, L.R.; Roberts, N.D.; Roberts, S.A.; Robertson, A.G.; Robertson, A.J.; Rodriguez, J.B.; Rodriguez-Martin, B.; Rodríguez-González, F.G.; Roehrl, M.H.A.; Rohde, M.; Rokutan, H.; Romieu, G.; Rooman, I.; Roques, T.; Rosebrock, D.; Rosenberg, M.; Rosenstiel, P.C.; Rosenwald, A.; Rowe, E.W.; Royo, R.; Rozen, S.G.; Rubanova, Y.; Rubin, M.A.; Rubio-Perez, C.; Rudneva, V.A.; Rusev, B.C.; Ruzzenente, A.; Rätsch, G.; Sabarinathan, R.; Sabelnykova, V.Y.; Sadeghi, S.; Sahinalp, S.C.; Saini, N.; Saito-Adachi, M.; Saksena, G.; Salcedo, A.; Salgado, R.; Salichos, L.; Sallari, R.; Saller, C.; Salvia, R.; Sam, M.; Samra, J.S.; Sanchez-Vega, F.; Sander, C.; Sanders, G.; Sarin, R.; Sarrafi, I.; Sasaki-Oku, A.; Sauer, T.; Sauter, G.; Saw, R.P.M.; Scardoni, M.; Scarlett, C.J.; Scarpa, A.; Scelo, G.; Schadendorf, D.; Schein, J.E.; Schilhabel, M.B.; Schlesner, M.; Schlomm, T.; Schmidt, H.K.; Schramm, S-J.; Schreiber, S.; Schultz, N.; Schumacher, S.E.; Schwarz, R.F.; Scolyer, R.A.; Scott, D.; Scully, R.; Seethala, R.; Segre, A.V.; Selander, I.; Semple, C.A.; Senbabaoglu, Y.; Sengupta, S.; Sereni, E.; Serra, S.; Sgroi, D.C.; Shackleton, M.; Shah, N.C.; Shahabi, S.; Shang, C.A.; Shang, P.; Shapira, O.; Shelton, T.; Shen, C.; Shen, H.; Shepherd, R.; Shi, R.; Shi, Y.; Shiah, Y-J.; Shibata, T.; Shih, J.; Shimizu, E.; Shimizu, K.; Shin, S.J.; Shiraishi, Y.; Shmaya, T.; Shmulevich, I.; Shorser, S.I.; Short, C.; Shrestha, R.; Shringarpure, S.S.; Shriver, C.; Shuai, S.; Sidiropoulos, N.; Siebert, R.; Sieuwerts, A.M.; Sieverling, L.; Signoretti, S.; Sikora, K.O.; Simbolo, M.; Simon, R.; Simons, J.V.; Simpson, J.T.; Simpson, P.T.; Singer, S.; Sinnott-Armstrong, N.; Sipahimalani, P.; Skelly, T.J.; Smid, M.; Smith, J.; Smith-McCune, K.; Socci, N.D.; Sofia, H.J.; Soloway, M.G.; Song, L.; Sood, A.K.; Sothi, S.; Sotiriou, C.; Soulette, C.M.; Span, P.N.; Spellman, P.T.; Sperandio, N.; Spillane, A.J.; Spiro, O.; Spring, J.; Staaf, J.; Stadler, P.F.; Staib, P.; Stark, S.G.; Stebbings, L.; Stefánsson, Ó.A.; Stegle, O.; Stein, L.D.; Stenhouse, A.; Stewart, C.; Stilgenbauer, S.; Stobbe, M.D.; Stratton, M.R.; Stretch, J.R.; Struck, A.J.; Stuart, J.M.; Stunnenberg, H.G.; Su, H.; Su, X.; Sun, R.X.; Sungalee, S.; Susak, H.; Suzuki, A.; Sweep, F.; Szczepanowski, M.; Sültmann, H.; Yugawa, T.; Tam, A.; Tamborero, D.; Tan, B.K.T.; Tan, D.; Tan, P.; Tanaka, H.; Taniguchi, H.; Tanskanen, T.J.; Tarabichi, M.; Tarnuzzer, R.; Tarpey, P.; Taschuk, M.L.; Tatsuno, K.; Tavaré, S.; Taylor, D.F.; Taylor-Weiner, A.; Teague, J.W.; Teh, B.T.; Tembe, V.; Temes, J.; Thai, K.; Thayer, S.P.; Thiessen, N.; Thomas, G.; Thomas, S.; Thompson, A.; Thompson, A.M.; Thompson, J.F.F.; Thompson, R.H.; Thorne, H.; Thorne, L.B.; Thorogood, A.; Tiao, G.; Tijanic, N.; Timms, L.E.; Tirabosco, R.; Tojo, M.; Tommasi, S.; Toon, C.W.; Toprak, U.H.; Torrents, D.; Tortora, G.; Tost, J.; Totoki, Y.; Townend, D.; Traficante, N.; Treilleux, I.; Trotta, J-R.; Trümper, L.H.P.; Tsao, M.; Tsunoda, T.; Tubio, J.M.C.; Tucker, O.; Turkington, R.; Turner, D.J.; Tutt, A.; Ueno, M.; Ueno, N.T.; Umbricht, C.; Umer, H.M.; Underwood, T.J.; Urban, L.; Urushidate, T.; Ushiku, T.; Uusküla-Reimand, L.; Valencia, A.; Van Den Berg, D.J.; Van Laere, S.; Van Loo, P.; Van Meir, E.G.; Van den Eynden, G.G.; Van der Kwast, T.; Vasudev, N.; Vazquez, M.; Vedururu, R.; Veluvolu, U.; Vembu, S.; Verbeke, L.P.C.; Vermeulen, P.; Verrill, C.; Viari, A.; Vicente, D.; Vicentini, C.; VijayRaghavan, K.; Viksna, J.; Vilain, R.E.; Villasante, I.; Vincent-Salomon, A.; Visakorpi, T.; Voet, D.; Vyas, P.; Vázquez-García, I.; Waddell, N.M.; Waddell, N.; Wadelius, C.; Wadi, L.; Wagener, R.; Wala, J.A.; Wang, J.; Wang, J.; Wang, L.; Wang, Q.; Wang, W.; Wang, Y.; Wang, Z.; Waring, P.M.; Warnatz, H-J.; Warrell, J.; Warren, A.Y.; Waszak, S.M.; Wedge, D.C.; Weichenhan, D.; Weinberger, P.; Weinstein, J.N.; Weischenfeldt, J.; Weisenberger, D.J.; Welch, I.; Wendl, M.C.; Werner, J.; Whalley, J.P.; Wheeler, D.A.; Whitaker, H.C.; Wigle, D.; Wilkerson, M.D.; Williams, A.; Wilmott, J.S.; Wilson, G.W.; Wilson, J.M.; Wilson, R.K.; Winterhoff, B.; Wintersinger, J.A.; Wiznerowicz, M.; Wolf, S.; Wong, B.H.; Wong, T.; Wong, W.; Woo, Y.; Wood, S.; Wouters, B.G.; Wright, A.J.; Wright, D.W.; Wright, M.H.; Wu, C-L.; Wu, D-Y.; Wu, G.; Wu, J.; Wu, K.; Wu, Y.; Wu, Z.; Xi, L.; Xia, T.; Xiang, Q.; Xiao, X.; Xing, R.; Xiong, H.; Xu, Q.; Xu, Y.; Xue, H.; Yachida, S.; Yakneen, S.; Yamaguchi, R.; Yamaguchi, T.N.; Yamamoto, M.; Yamamoto, S.; Yamaue, H.; Yang, F.; Yang, H.; Yang, J.Y.; Yang, L.; Yang, L.; Yang, S.; Yang, T-P.; Yang, Y.; Yao, X.; Yaspo, M-L.; Yates, L.; Yau, C.; Ye, C.; Ye, K.; Yellapantula, V.D.; Yoon, C.J.; Yoon, S-S.; Yousif, F.; Yu, J.; Yu, K.; Yu, W.; Yu, Y.; Yuan, K.; Yuan, Y.; Yuen, D.; Yung, C.K.; Zaikova, O.; Zamora, J.; Zapatka, M.; Zenklusen, J.C.; Zenz, T.; Zeps, N.; Zhang, C-Z.; Zhang, F.; Zhang, H.; Zhang, H.; Zhang, H.; Zhang, J.; Zhang, J.; Zhang, J.; Zhang, X.; Zhang, X.; Zhang, Y.; Zhang, Z.; Zhao, Z.; Zheng, L.; Zheng, X.; Zhou, W.; Zhou, Y.; Zhu, B.; Zhu, H.; Zhu, J.; Zhu, S.; Zou, L.; Zou, X.; deFazio, A.; van As, N.; van Deurzen, C.H.M.; van de Vijver, M.J.; van’t Veer, L.; von Mering, C. The evolutionary history of 2,658 cancers. Nature, 2020, 578(7793), 122-128.
[http://dx.doi.org/10.1038/s41586-019-1907-7] [PMID: 32025013]

Boutin, A.T.; Liao, W.T.; Wang, M.; Hwang, S.S.; Karpinets, T.V.; Cheung, H.; Chu, G.C.; Jiang, S.; Hu, J.; Chang, K.; Vilar, E.; Song, X.; Zhang, J.; Kopetz, S.; Futreal, A.; Wang, Y.A.; Kwong, L.N.; DePinho, R.A. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev., 2017, 31(4), 370-382.
[http://dx.doi.org/10.1101/gad.293449.116] [PMID: 28289141]

Quirke, P.; Risio, M.; Lambert, R.; von Karsa, L.; Vieth, M. Quality assurance in pathology in colorectal cancer screening and diagnosis—European recommendations. Virchows Arch., 2011, 458(1), 1-19.
[http://dx.doi.org/10.1007/s00428-010-0977-6] [PMID: 21061133]

Snover, D.C. Update on the serrated pathway to colorectal carcinoma. Hum. Pathol., 2011, 42(1), 1-10.
[http://dx.doi.org/10.1016/j.humpath.2010.06.002] [PMID: 20869746]

Takai, D.; Jones, P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci., 2002, 99(6), 3740-3745.
[http://dx.doi.org/10.1073/pnas.052410099] [PMID: 11891299]

Toyota, M.; Ahuja, N.; Ohe-Toyota, M.; Herman, J.G.; Baylin, S.B.; Issa, J.P.J. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci., 1999, 96(15), 8681-8686.
[http://dx.doi.org/10.1073/pnas.96.15.8681] [PMID: 10411935]

Noffsinger, A.E. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu. Rev. Pathol., 2009, 4(1), 343-364.
[http://dx.doi.org/10.1146/annurev.pathol.4.110807.092317] [PMID: 19400693]

East, J.E.; Saunders, B.P.; Jass, J.R. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol. Clin. North Am., 2008, 37(1), 25-46, v.
[http://dx.doi.org/10.1016/j.gtc.2007.12.014] [PMID: 18313538]

Snover, D.C. Serrated polyps of the large intestine. Semin. Diagn. Pathol., 2005, 22(4), 301-308.
[http://dx.doi.org/10.1053/j.semdp.2006.04.003] [PMID: 16939058]

Snover, D.C.; Jass, J.R.; Fenoglio-Preiser, C.; Batts, K.P. Serrated polyps of the large intestine: A morphologic and molecular review of an evolving concept. Am. J. Clin. Pathol., 2005, 124(3), 380-391.
[http://dx.doi.org/10.1309/V2EPTPLJRB3FGHJL] [PMID: 16191506]

Jeong, M.; Goodell, M.A. New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells. Exp. Hematol., 2014, 42(8), 609-617.
[http://dx.doi.org/10.1016/j.exphem.2014.04.008] [PMID: 24993071]

Kaur, H.; Bhalla, S.; Raghava, G.P.S. Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles. PLoS One, 2019, 14(9), e0221476.
[http://dx.doi.org/10.1371/journal.pone.0221476] [PMID: 31490960]

Hu, J.; Zhao, F.; Huang, B.; Ran, J.; Chen, M.; Liu, H.; Deng, Y.; Zhao, X.; Han, X. An eight-CpG-based methylation classifier for preoperative discriminating early and advanced-late stage of colorectal cancer. Front. Genet., 2021, 11, 614160.
[http://dx.doi.org/10.3389/fgene.2020.614160] [PMID: 33519917]

Nazemalhosseini Mojarad, E.; Kuppen, P.J.; Aghdaei, H.A.; Zali, M.R. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol. Hepatol. Bed Bench, 2013, 6(3), 120-128.
[PMID: 24834258]

Jass, J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology, 2007, 50(1), 113-130.
[http://dx.doi.org/10.1111/j.1365-2559.2006.02549.x] [PMID: 17204026]

De Rosa, M.; Rega, D.; Costabile, V.; Duraturo, F.; Niglio, A.; Izzo, P.; Pace, U.; Delrio, P. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therap. Adv. Gastroenterol., 2016, 9(6), 861-886.
[http://dx.doi.org/10.1177/1756283X16659790] [PMID: 27803741]

Barault, L.; Charon-Barra, C.; Jooste, V.; de la Vega, M.F.; Martin, L.; Roignot, P.; Rat, P.; Bouvier, A.M.; Laurent-Puig, P.; Faivre, J.; Chapusot, C.; Piard, F. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res., 2008, 68(20), 8541-8546.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-1171] [PMID: 18922929]

Yagi, K.; Akagi, K.; Hayashi, H.; Nagae, G.; Tsuji, S.; Isagawa, T. Three epigenotypes of DNA methylation in human colorectal cancer. Clin. Cancer Res., 2010, 16, 21-33.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2006] [PMID: 20028768]

Shen, L.; Catalano, P.J.; Benson, A.B., III; O’Dwyer, P.; Hamilton, S.R.; Issa, J.P.J. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res., 2007, 13(20), 6093-6098.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-1011] [PMID: 17947473]

Guinney, J.; Dienstmann, R.; Wang, X.; de Reyniès, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; Bot, B.M.; Morris, J.S.; Simon, I.M.; Gerster, S.; Fessler, E.; De Sousa E Melo, F.; Missiaglia, E.; Ramay, H.; Barras, D.; Homicsko, K.; Maru, D.; Manyam, G.C.; Broom, B.; Boige, V.; Perez-Villamil, B.; Laderas, T.; Salazar, R.; Gray, J.W.; Hanahan, D.; Tabernero, J.; Bernards, R.; Friend, S.H.; Laurent-Puig, P.; Medema, J.P.; Sadanandam, A.; Wessels, L.; Delorenzi, M.; Kopetz, S.; Vermeulen, L.; Tejpar, S. The consensus molecular subtypes of colorectal cancer. Nat. Med., 2015, 21(11), 1350-1356.
[http://dx.doi.org/10.1038/nm.3967] [PMID: 26457759]

Rebersek, M. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision. Radiol. Oncol., 2020, 54(3), 272-277.
[http://dx.doi.org/10.2478/raon-2020-0031] [PMID: 32463385]

Park, S.C.; Sohn, D.K.; Kim, M.J.; Chang, H.J.; Han, K.S.; Hyun, J.H.; Joo, J.; Oh, J.H. Phase II clinical trial to evaluate the efficacy of transanal endoscopic total mesorectal excision for rectal cancer. Dis. Colon Rectum, 2018, 61(5), 554-560.
[http://dx.doi.org/10.1097/DCR.0000000000001058] [PMID: 29624549]

Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.; Siegel, R.L. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin., 2019, 69(5), 363-385.
[http://dx.doi.org/10.3322/caac.21565] [PMID: 31184787]

Ogura, A.; Konishi, T.; Cunningham, C.; Garcia-Aguilar, J.; Iversen, H.; Toda, S.; Lee, I.K.; Lee, H.X.; Uehara, K.; Lee, P.; Putter, H.; van de Velde, C.J.H.; Beets, G.L.; Rutten, H.J.T.; Kusters, M. Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: Results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J. Clin. Oncol., 2019, 37(1), 33-43.
[http://dx.doi.org/10.1200/JCO.18.00032] [PMID: 30403572]

Johdi, N.A.; Sukor, N.F. Colorectal cancer immunotherapy: Options and strategies. Front. Immunol., 2020, 11, 1624.
[http://dx.doi.org/10.3389/fimmu.2020.01624] [PMID: 33042104]

Pardini, B.; Kumar, R.; Naccarati, A.; Novotny, J.; Prasad, R.B.; Forsti, A.; Hemminki, K.; Vodicka, P.; Lorenzo Bermejo, J. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br. J. Clin. Pharmacol., 2011, 72(1), 162-163.
[http://dx.doi.org/10.1111/j.1365-2125.2010.03892.x] [PMID: 21204909]

Calvo, E.; Cortés, J.; Rodríguez, J.; Fernández-Hidalgo, Ó.; Rebollo, J.; Martín-Algarra, S.; García-Foncillas, J.; Martínez-Monge, R.; de Irala, J.; Brugarolas, A. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: A phase II study. Clin. Colorectal Cancer, 2002, 2(2), 104-110.
[http://dx.doi.org/10.3816/CCC.2002.n.016] [PMID: 12453325]

Yuan, Y.; Xiao, W.W.; Xie, W.H.; Cai, P.Q.; Wang, Q.X.; Chang, H.; Chen, B.Q.; Zhou, W.H.; Zeng, Z.F.; Wu, X.J.; Liu, Q.; Li, L.R.; Zhang, R.; Gao, Y.H. Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: A potential improvement to overall survival and decrease to multivisceral resection. BMC Cancer, 2021, 21(1), 179.
[http://dx.doi.org/10.1186/s12885-021-07894-6] [PMID: 33607964]

Zheng, S.; Tao, W. Identification of novel transcriptome signature as a potential prognostic biomarker for anti-angiogenic therapy in glioblastoma multiforme. Cancers, 2020, 12
[http://dx.doi.org/10.3390/cancers12092368] [PMID: 33804433]

Hao, Z.; Parasramka, S.; Chen, Q.; Jacob, A.; Huang, B.; Mullett, T.; Benson, A.B. Neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer in non-academic and academic programs. Oncologist, 2022, 28(1), 48-58.
[http://dx.doi.org/10.1093/oncolo/oyac209] [PMID: 36200844]

Normanno, N.; Tejpar, S.; Morgillo, F.; De Luca, A.; Van Cutsem, E.; Ciardiello, F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol., 2009, 6(9), 519-527.
[http://dx.doi.org/10.1038/nrclinonc.2009.111] [PMID: 19636327]

Shen, W.D.; Chen, H.L.; Liu, P.F. EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: A meta-analysis. Chin. J. Cancer Res., 2014, 26(1), 59-71.
[http://dx.doi.org/10.3978/j.issn.1000-9604.2014.01.10] [PMID: 24653627]

Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist, 2007, 12(3), 356-361.
[http://dx.doi.org/10.1634/theoncologist.12-3-356] [PMID: 17405901]

Tang, P.A.; Cohen, S.J.; Kollmannsberger, C.; Bjarnason, G.; Virik, K.; MacKenzie, M.J.; Lourenco, L.; Wang, L.; Chen, A.; Moore, M.J. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin. Cancer Res., 2012, 18(21), 6023-6031.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-3252] [PMID: 22977191]

Piawah, S.; Venook, A.P. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer, 2019, 125(23), 4139-4147.
[http://dx.doi.org/10.1002/cncr.32163] [PMID: 31433498]

Wojtukiewicz, M.Z.; Rek, M.M.; Karpowicz, K.; Górska, M.; Polityńska, B.; Wojtukiewicz, A.M.; Moniuszko, M.; Radziwon, P.; Tucker, S.C.; Honn, K.V. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev., 2021, 40(3), 949-982.
[http://dx.doi.org/10.1007/s10555-021-09976-0] [PMID: 34236546]

Patsoukis, N.; Brown, J.; Petkova, V.; Liu, F.; Li, L.; Boussiotis, V.A. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal., 2012, 5(230), ra46.
[http://dx.doi.org/10.1126/scisignal.2002796] [PMID: 22740686]

García-Aranda, M.; Redondo, M. Immunotherapy: A challenge of breast cancer treatment. Cancers, 2019, 11(12), 1822.
[http://dx.doi.org/10.3390/cancers11121822] [PMID: 31756919]

FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer. 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer#:~:text=On%20July%2031%2C%202017%2C%20the,colorectal%20cancer%20that%20has%20progressed

Marcus, L.; Lemery, S.J.; Keegan, P.; Pazdur, R. FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res., 2019, 25(13), 3753-3758.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-4070] [PMID: 30787022]

Administration, F.a.D.. FDA approves first-line immunotherapy for patients with MSI-H/dMMR metastatic. 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer#:~:text=On%20June%2029%2C%202020%2C%20the,deficient%20(dMMR)%20colorectal%20cancer.

André, T.; Shiu, K.K.; Kim, T.W.; Jensen, B.V.; Jensen, L.H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; de la Fouchardiere, C.; Rivera, F.; Elez, E.; Bendell, J.; Le, D.T.; Yoshino, T.; Van Cutsem, E.; Yang, P.; Farooqui, M.Z.H.; Marinello, P.; Diaz, L.A., Jr Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med., 2020, 383(23), 2207-2218.
[http://dx.doi.org/10.1056/NEJMoa2017699] [PMID: 33264544]

FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication

FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer. 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer

Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; Biedrzycki, B.; Donehower, R.C.; Zaheer, A.; Fisher, G.A.; Crocenzi, T.S.; Lee, J.J.; Duffy, S.M.; Goldberg, R.M.; de la Chapelle, A.; Koshiji, M.; Bhaijee, F.; Huebner, T.; Hruban, R.H.; Wood, L.D.; Cuka, N.; Pardoll, D.M.; Papadopoulos, N.; Kinzler, K.W.; Zhou, S.; Cornish, T.C.; Taube, J.M.; Anders, R.A.; Eshleman, J.R.; Vogelstein, B.; Diaz, L.A., Jr PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med., 2015, 372(26), 2509-2520.
[http://dx.doi.org/10.1056/NEJMoa1500596] [PMID: 26028255]

de Wied, D. Peptide hormones and neuropeptides: birds of a feather. Trends Neurosci., 2000, 23(3), 113.
[http://dx.doi.org/10.1016/S0166-2236(99)01511-8] [PMID: 10675911]

Burbach, J.P. Neuropeptides from concept to online database. J. Pharmacol, 2010, 626, 27-48.

Hökfelt, T.; Bartfai, T.; Bloom, F. Neuropeptides: opportunities for drug discovery. Lancet Neurol., 2003, 2(8), 463-472.
[http://dx.doi.org/10.1016/S1474-4422(03)00482-4] [PMID: 12878434]

Romanova, E.V.; Sweedler, J.V. Peptidomics for the discovery and characterization of neuropeptides and hormones. Trends Pharmacol. Sci., 2015, 36(9), 579-586.
[http://dx.doi.org/10.1016/j.tips.2015.05.009] [PMID: 26143240]

Steinhoff, M.S.; von Mentzer, B.; Geppetti, P.; Pothoulakis, C.; Bunnett, N.W. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol. Rev., 2014, 94(1), 265-301.
[http://dx.doi.org/10.1152/physrev.00031.2013] [PMID: 24382888]

Martínez, A.N.; Philipp, M.T. Substance P and neuoquinin-1 receptor antagonists in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system. J. Neurol. Neuromedicine, 2016, 1, 29-36.
[http://dx.doi.org/10.29245/2572.942X/2016/2.1020] [PMID: 27430034]

Werge, T. The tachykinin tale: Molecular recognition in a historical perspective. J. Mol. Recognit., 2007, 20(3), 145-153.
[http://dx.doi.org/10.1002/jmr.822] [PMID: 17444559]

Bremer, A.A.; Leeman, S.E.; Boyd, N.D. The common C-terminal sequences of substance P and neurokinin A contact the same region of the NK-1 receptor. FEBS Lett., 2000, 486(1), 43-48.
[http://dx.doi.org/10.1016/S0014-5793(00)02228-6] [PMID: 11108840]

Goldsmith, L.E.; Kwatra, M.M. Tachykinin/substance P/neurokinin-1 receptors.Encyclopedia of Biological Chemistry; Academic Press: Waltham, MA, 2013, pp. 360-365.

Lorestani, S.; Ghahremanloo, A.; Jangjoo, A.; Abedi, M.; Hashemy, S.I. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer. Mol. Biol. Rep., 2020, 47(5), 3469-3474.
[http://dx.doi.org/10.1007/s11033-020-05432-4] [PMID: 32277443]

García-Aranda, M.; Téllez, T.; McKenna, L.; Redondo, M. Neurokinin-1 receptor-1 (NK-1R) antagonists as a new strategy to overcome cancer resistance. Cancers, 2022, 14(9), 2255.
[http://dx.doi.org/10.3390/cancers14092255] [PMID: 35565383]

Patacchini, R.; Maggi, C.A. Peripheral tachykinin receptors as targets for new drugs. Eur. J. Pharmacol., 2001, 429(1-3), 13-21.
[http://dx.doi.org/10.1016/S0014-2999(01)01301-2] [PMID: 11698023]

NCBI TAC1 Precursor de taquiquinina 1 [Homo Sapiens (humano)]. Available from: https://www.ncbi.nlm.nih.gov/gene/6863 (Accessed August 16, 2022).

Page, N.M. New challenges in the study of the mammalian tachykinins. Peptides, 2005, 26(8), 1356-1368.
[http://dx.doi.org/10.1016/j.peptides.2005.03.030] [PMID: 16042976]

El gen TAC3 de la base de datos de genes humanos. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TAC3 (Accessed August 16, 2022).

NCBI TAC3 Precursor de taquiquinina 3 [Homo Sapiens (humano)]. Available from: https://www.ncbi.nlm.nih.gov/gene/6866 (Accessed August 16, 2022).

UNIProt UniProtKB–Q86UU9 (TKN4_HUMAN). Available from: https://www.uniprot.org/uniprot/Q86UU9 (Accessed August 16, 2022).

NCBI TAC4 Precursor de taquiquinina 4 [Homo Sapiens (humano)]. Available from: https://www.ncbi.nlm.nih.gov/gene/255061 (Accessed August 16, 2022).

Ho, W.Z.; Lai, J.P.; Zhu, X.H.; Uvaydova, M.; Douglas, S.D. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J. Immunol., 1997, 159(11), 5654-5660.
[http://dx.doi.org/10.4049/jimmunol.159.11.5654] [PMID: 9548509]

McGillis, J.P.; Mitsuhashi, M.; Payan, D.G. Immunological properties of substance P. In: Psychoneuroimmunology; Ader, R., Ed.; Academic Press, 1991; pp. 209-223.
[http://dx.doi.org/10.1016/B978-0-12-043780-1.50011-7]

Moore, T.C.; Lami, J.L.; Spruck, C.H. Substance P increases lymphocyte traffic and lymph flow through peripheral lymph nodes of sheep. Immunology, 1989, 67(1), 109-114.
[PMID: 2472354]

Stanisz, A.M.; Befus, D.; Bienenstock, J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer’s patches, mesenteric lymph nodes, and spleen. J. Immunol., 1986, 136(1), 152-156.
[http://dx.doi.org/10.4049/jimmunol.136.1.152] [PMID: 2415614]

Lotz, M.; Vaughan, J.H.; Carson, D.A. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science, 1988, 241(4870), 1218-1221.
[http://dx.doi.org/10.1126/science.2457950] [PMID: 2457950]

Hartung, H.P.; Toyka, K.V. Activation of macrophages by substance P: Induction of oxidative burst and thromboxane release. Eur. J. Pharmacol., 1983, 89(3-4), 301-305.
[http://dx.doi.org/10.1016/0014-2999(83)90511-3] [PMID: 6191998]

Muñoz, M.; Coveñas, R. Neurokinin receptor antagonism: A patent review (2014-present). Expert Opin. Ther. Pat., 2020, 30(7), 527-539.
[http://dx.doi.org/10.1080/13543776.2020.1769599] [PMID: 32401556]

Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454(7203), 436-444.
[http://dx.doi.org/10.1038/nature07205] [PMID: 18650914]

Rosso, M.; Muñoz, M.; Berger, M. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal, 2012, 2012, 1-21.
[http://dx.doi.org/10.1100/2012/381434] [PMID: 22545017]

Feng, F.; Yang, J.; Tong, L.; Yuan, S.; Tian, Y.; Hong, L.; Wang, W.; Zhang, H. Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells. Cell Biol. Int., 2011, 35(6), 623-629.
[http://dx.doi.org/10.1042/CBI20100229] [PMID: 21091434]

Bar-Shavit, Z.; Goldman, R.; Stabinsky, Y.; Gottlieb, P.; Fridkin, M.; Teichberg, V.I.; Blumberg, S. Enhancement of phagocytosis - A newly found activity of Substance P residing in its N-terminal tetrapeptide sequence. Biochem. Biophys. Res. Commun., 1980, 94(4), 1445-1451.
[http://dx.doi.org/10.1016/0006-291X(80)90581-1] [PMID: 6156684]

Kage, R.; Leeman, S.E.; Boyd, N.D. Biochemical characterization of two different forms of the substance P receptor in rat submaxillary gland. J. Neurochem., 1993, 60(1), 347-351.
[http://dx.doi.org/10.1111/j.1471-4159.1993.tb05857.x] [PMID: 8380195]

UniProt UniProtKB-P25103. Available from: https://www.uniprot.org/uniprot/P25103 (Accessed Jul 5, 2023)

Gerard, N.P.; Garraway, L.A.; Eddy, R.L. Human substance P receptor (NK-1): Gene organization, chromosomal localization, and functional expression of cDNA clones. Biochemistry, 1991, 30, 10640-10646.
[http://dx.doi.org/10.1021/bi00108a006] [PMID: 1657150]

O’Connor, T.M.; O’Connell, J.; O’Brien, D.I.; Goode, T.; Bredin, C.P.; Shanahan, F. The role of substance P in inflammatory disease. J. Cell. Physiol., 2004, 201(2), 167-180.
[http://dx.doi.org/10.1002/jcp.20061] [PMID: 15334652]

Lai, J.P.; Lai, S.; Tuluc, F.; Tansky, M.F.; Kilpatrick, L.E.; Leeman, S.E.; Douglas, S.D. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc. Natl. Acad. Sci., 2008, 105(34), 12605-12610.
[http://dx.doi.org/10.1073/pnas.0806632105] [PMID: 18713853]

Ghahremanloo, A.; Javid, H.; Afshari, A.R.; Hashemy, S.I. Investigation of the role of neurokinin-1 receptor inhibition with aprepitant in apoptotic cell death via PI3K/Akt/NF- κ B signal transduction pathways in colon cancer cells. BioMed Res. Int., 2021, 2021, 1-10.
[http://dx.doi.org/10.1155/2021/1383878] [PMID: 34395609]

Spitsin, S.; Pappa, V.; Douglas, S.D. Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling. J. Leukoc. Biol., 2018, 103(6), 1043-1051.
[http://dx.doi.org/10.1002/JLB.3MIR0817-348R] [PMID: 29345372]

Ramkissoon, S.H.; Patel, P.S.; Taborga, M.; Rameshwar, P. Nuclear factor kappaB is critical for truncated neurokinin-1 receptor expression in breast cancer: Implication for quiescence of breast cancer cells within the bone marrow stroma. Cancer Res., 2007, 67, 1653-1659.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-3813] [PMID: 17308106]

Patel, H.J.; Ramkissoon, S.H.; Patel, P.S.; Rameshwar, P. Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc. Natl. Acad. Sci., 2005, 102(48), 17436-17441.
[http://dx.doi.org/10.1073/pnas.0506351102] [PMID: 16291810]

Bigioni, M.; Benzo, A.; Irrissuto, C.; Maggi, C.A.; Goso, C. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs, 2005, 16(10), 1083-1089.
[http://dx.doi.org/10.1097/00001813-200511000-00007] [PMID: 16222150]

Gao, X.; Wang, Z. Difference in expression of two neurokinin-1 receptors in adenoma and carcinoma from patients that underwent radical surgery for colorectal carcinoma. Oncol. Lett., 2017, 14(3), 3729-3733.
[http://dx.doi.org/10.3892/ol.2017.6588] [PMID: 28927139]

Isorna, I.; Esteban, F.; Solanellas, J.; Coveñas, R.; Muñoz, M. The substance P and neurokinin-1 receptor system in human thyroid cancer: An immunohistochemical study. Eur. J. Histochem., 2020, 64(2), 3117.
[http://dx.doi.org/10.4081/ejh.2020.3117] [PMID: 32363847]

Hennig, I.M.; Laissue, J.A.; Horisberger, U.; Reubi, J.C. Substance-P receptors in human primary neoplasms: Tumoral and vascular localization. Int. J. Cancer, 1995, 61(6), 786-792.
[http://dx.doi.org/10.1002/ijc.2910610608] [PMID: 7790112]

Muñoz, M.; Coveñas, R. Involvement of substance P and the NK-1 receptor in pancreatic cancer. World J. Gastroenterol., 2014, 20(9), 2321-2334.
[http://dx.doi.org/10.3748/wjg.v20.i9.2321] [PMID: 24605029]

Javid, H.; Asadi, J.; Zahedi Avval, F.; Afshari, A.R.; Hashemy, S.I. The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways. Mol. Biol. Rep., 2020, 47(3), 2253-2263.
[http://dx.doi.org/10.1007/s11033-020-05330-9] [PMID: 32072401]

Douglas, S.D.; Leeman, S.E. Neurokinin-1 receptor: Functional significance in the immune system in reference to selected infections and inflammation. Ann. N. Y. Acad. Sci., 2011, 1217(1), 83-95.
[http://dx.doi.org/10.1111/j.1749-6632.2010.05826.x] [PMID: 21091716]

Liu, R.; Chen, Y.; Liu, G.; Li, C.; Song, Y.; Cao, Z.; Li, W.; Hu, J.; Lu, C.; Liu, Y. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis., 2020, 11(9), 797.
[http://dx.doi.org/10.1038/s41419-020-02998-6] [PMID: 32973135]

Salaroglio, I.C.; Mungo, E.; Gazzano, E.; Kopecka, J.; Riganti, C. ERK is a pivotal player of chemo-immune-resistance in cancer. Int. J. Mol. Sci., 2019, 20(10), 2505.
[http://dx.doi.org/10.3390/ijms20102505] [PMID: 31117237]

DeFea, K.A.; Vaughn, Z.D.; O’Bryan, E.M.; Nishijima, D.; Déry, O.; Bunnett, N.W. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc. Natl. Acad. Sci., 2000, 97(20), 11086-11091.
[http://dx.doi.org/10.1073/pnas.190276697] [PMID: 10995467]

Deng, X.T.; Tang, S.M.; Wu, P.Y.; Li, Q.P.; Ge, X.X.; Xu, B.M.; Wang, H.S.; Miao, L. SP/NK-1R promotes gallbladder cancer cell proliferation and migration. J. Cell. Mol. Med., 2019, 23(12), 7961-7973.
[http://dx.doi.org/10.1111/jcmm.14230] [PMID: 30903649]

Bentires-Alj, M.; Barbu, V.; Fillet, M.; Chariot, A.; Relic, B.; Jacobs, N.; Gielen, J.; Merville, M.P.; Bours, V. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 2003, 22(1), 90-97.
[http://dx.doi.org/10.1038/sj.onc.1206056] [PMID: 12527911]

Di Maio, M.; Bria, E.; Banna, G.L.; Puglisi, F.; Garassino, M.C.; Lorusso, D.; Perrone, F. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors. Anticancer Drugs, 2013, 24(2), 99-111.
[http://dx.doi.org/10.1097/CAD.0b013e328359d7ba] [PMID: 23165435]

Cassidy, J.; Clarke, S.; Díaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.S.; Rivera, F.; Couture, F.; Sirzén, F.; Saltz, L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol., 2008, 26(12), 2006-2012.
[http://dx.doi.org/10.1200/JCO.2007.14.9898] [PMID: 18421053]

Shimokawa, M.; Hayashi, T.; Nishimura, J.; Satoh, T.; Fukunaga, M.; Matsui, R.; Tsuji, Y.; Mizuki, F.; Kogawa, T. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. BMC Cancer, 2021, 21(1), 1111.
[http://dx.doi.org/10.1186/s12885-021-08860-y] [PMID: 34656107]

Vidall, C.; Fernández-Ortega, P.; Cortinovis, D.; Jahn, P.; Amlani, B.; Scotté, F. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: A cross-sectional multinational survey. Support. Care Cancer, 2015, 23(11), 3297-3305.
[http://dx.doi.org/10.1007/s00520-015-2750-5] [PMID: 25953380]

Hesketh, P.J. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 2008, 358(23), 2482-2494.
[http://dx.doi.org/10.1056/NEJMra0706547] [PMID: 18525044]

Navari, R.M. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin. Drug Saf., 2016, 15(3), 343-356.
[http://dx.doi.org/10.1517/14740338.2016.1135899] [PMID: 26699406]

Hesketh, P.J.; Kris, M.G.; Basch, E.; Bohlke, K.; Barbour, S.Y.; Clark-Snow, R.A.; Danso, M.A.; Dennis, K.; Dupuis, L.L.; Dusetzina, S.B.; Eng, C.; Feyer, P.C.; Jordan, K.; Noonan, K.; Sparacio, D.; Somerfield, M.R.; Lyman, G.H. Antiemetics: Update to the american society of clinical oncology clinical practice guideline. J. Clin. Oncol., 2017, 35(28), 3240-3261.
[http://dx.doi.org/10.1200/JCO.2017.74.4789] [PMID: 28759346]

Navari, R.M.; Aapro, M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 2016, 374(14), 1356-1367.
[http://dx.doi.org/10.1056/NEJMra1515442] [PMID: 27050207]

Schwartzberg, L.S.; Modiano, M.R.; Rapoport, B.L.; Chasen, M.R.; Gridelli, C.; Urban, L.; Poma, A.; Arora, S.; Navari, R.M.; Schnadig, I.D. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: A randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol., 2015, 16(9), 1071-1078.
[http://dx.doi.org/10.1016/S1470-2045(15)00034-0] [PMID: 26272768]

Aapro, M. CINV: Patients still worrying after all these years. Cancer Support Care, 2018, 26, 5-9.
[http://dx.doi.org/10.1007/s00520-018-4131-3] [PMID: 29556808]

European Medicines Agency EMEND. INN-Aprepitant: Scientific Discussion. 2004. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/emend-epar-scientific-discussion_en.pdf (Accessed August 17, 2022)

Muñoz, M.; Coveñas, R. The neurokinin-1 receptor antagonist aprepitant: A smart bullet against cancer? Cancers, 2020, 12(9), 2682.
[http://dx.doi.org/10.3390/cancers12092682] [PMID: 32962202]

Robinson, P.; Kasembeli, M.; Bharadwaj, U.; Engineer, N.; Eckols, K.T.; Tweardy, D.J.; Substance, P. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance. BioMed Res. Int., 2016, 2016, 1-9.
[http://dx.doi.org/10.1155/2016/1959270] [PMID: 26981525]

Muñoz, M.; González-Ortega, A.; Salinas-Martín, M.V.; Carranza, A.; Garcia-Recio, S.; Almendro, V.; Coveñas, R. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. Int. J. Oncol., 2014, 45(4), 1658-1672.
[http://dx.doi.org/10.3892/ijo.2014.2565] [PMID: 25175857]

Nizam, E.; Erin, N. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P. Biomed. Pharmacother., 2018, 108, 263-270.
[http://dx.doi.org/10.1016/j.biopha.2018.09.013] [PMID: 30223097]

Zhang, X.W.; Li, L.; Hu, W.Q.; Hu, M.N.; Tao, Y.; Hu, H.; Miao, X.K.; Yang, W.L.; Zhu, Q.; Mou, L.Y. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR. Cell Death Dis., 2022, 13(1), 41.
[http://dx.doi.org/10.1038/s41419-021-04485-y] [PMID: 35013118]

Matalińska, J.; Świć, A.; Lipiński, P.; Misicka, A. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells. Folia Neuropathol., 2020, 58(3), 237-244.
[http://dx.doi.org/10.5114/fn.2020.100066] [PMID: 33099293]

Muñoz, M.; Coveñas, R. Involvement of substance P and the NK-1 receptor in cancer progression. Peptides, 2013, 48, 1-9.
[http://dx.doi.org/10.1016/j.peptides.2013.07.024] [PMID: 23933301]

Beirith, I.; Renz, B.W.; Mudusetti, S.; Ring, N.S.; Kolorz, J.; Koch, D.; Bazhin, A.V.; Berger, M.; Wang, J.; Angele, M.K.; D’Haese, J.G.; Guba, M.O.; Niess, H.; Andrassy, J.; Werner, J.; Ilmer, M. Identification of the neurokinin-1 receptor as targetable stratification factor for drug repurposing in pancreatic cancer. Cancers, 2021, 13(11), 2703.
[http://dx.doi.org/10.3390/cancers13112703] [PMID: 34070805]

Ebrahimi, S.; Mirzavi, F.; Aghaee-Bakhtiari, S.H.; Hashemy, S.I. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant. Biochim. Biophys. Acta Mol. Cell Res., 2022, 1869(5), 119221.
[http://dx.doi.org/10.1016/j.bbamcr.2022.119221] [PMID: 35134443]

Takei, S.; Ishibe, A.; Watanabe, J.; Watanabe, K.; Suwa, Y.; Suzuki, S.; Nakagawa, K.; Suwa, H.; Ota, M.; Ichikawa, Y.; Kunisaki, C.; Yamanaka, T.; Endo, I. Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: A prospective cohort study (YCOG1301). Int. J. Colorectal Dis., 2020, 35(12), 2323-2329.
[http://dx.doi.org/10.1007/s00384-020-03731-7] [PMID: 32860080]

Garnier, A.; Vykoukal, J.; Hubertus, J.; Alt, E.; Von Schweinitz, D.; Kappler, R.; Berger, M.; Ilmer, M. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Int. J. Oncol., 2015, 47(1), 151-160.
[http://dx.doi.org/10.3892/ijo.2015.3016] [PMID: 25998227]

Ghahremanloo, A.; Javid, H.; Afshari, A.R.; Hashemy, S.I. Investigation of the role of neurokinin-1 receptor inhibition using aprepitant in the apoptotic cell death through PI3K/Akt/NF-κB signal transduction pathways in colon cancer cells. BioMed Res. Int., 2021, 2021, 1-10.
[http://dx.doi.org/10.1155/2021/1383878] [PMID: 34395609]

Koon, H.W.; Zhao, D.; Na, X.; Moyer, M.P.; Pothoulakis, C. Metalloproteinases and transforming growth factor-α mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J. Biol. Chem., 2004, 279(44), 45519-45527.
[http://dx.doi.org/10.1074/jbc.M408523200] [PMID: 15319441]

Stucchi, A.F.; Shofer, S.; Leeman, S.; Materne, O.; Beer, E.; McClung, J.; Shebani, K.; Moore, F.; O’Brien, M.; Becker, J.M. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279(6), G1298-G1306.
[http://dx.doi.org/10.1152/ajpgi.2000.279.6.G1298] [PMID: 11093954]

Castagliuolo, I.; Morteau, O.; Keates, A.C.; Valenick, L.; Wang, C.C.; Zacks, J.; Lu, B.; Gerard, N.P.; Pothoulakis, C. Protective effects of neurokinin-1 receptor during colitis in mice: Role of the epidermal growth factor receptor. Br. J. Pharmacol., 2002, 136(2), 271-279.
[http://dx.doi.org/10.1038/sj.bjp.0704697] [PMID: 12010776]

Rosso, M.; Robles-Frías, M.J.; Coveñas, R.; Salinas-Martín, M.V.; Muñoz, M. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol., 2008, 29(4), 245-254.
[http://dx.doi.org/10.1159/000152942] [PMID: 18781096]

Pagán, B.; Isidro, A.A.; Coppola, D.; Chen, Z.; Ren, Y.; Wu, J.; Appleyard, C.B. Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res., 2010, 30(9), 3345-3353.
[PMID: 20944107]

Legi, A.; Rodriguez, E.; Eckols, T.K.; Mistry, C.; Robinson, P.; Substance, P. Substance P antagonism prevents chemotherapy-induced cardiotoxicity. Cancers, 2021, 13(7), 1732.
[http://dx.doi.org/10.3390/cancers13071732] [PMID: 33917491]

Rapoport, B.; Aapro, M.; Chasen, M.; Jordan, K.; Navari, R.; Schnadig, I.; Schwartzberg, L. Recent developments in the clinical pharmacology of rolapitant: Subanalyses in specific populations. Drug Des. Devel. Ther., 2017, 11, 2621-2629.
[http://dx.doi.org/10.2147/DDDT.S133943] [PMID: 28919712]

Lee, M.; McCloskey, M.; Staples, S. Prolonged use of aprepitant in metastatic breast cancer and a reduction in CA153 tumour marker levels. Int. J. Cancer Clin. Res., 2016, 3, 071.
[http://dx.doi.org/10.23937/2378-3419/3/6/1071]

Muñoz, M.; Crespo, J.C.; Crespo, J.P.; Coveñas, R. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. Mol. Clin. Oncol., 2019, 11(1), 50-54.
[http://dx.doi.org/10.3892/mco.2019.1857] [PMID: 31289677]

FDA. Approves first cancer treatment for any solid tumor with a specific genetic feature. 2017. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature (Accessed on: February 5, 2023)

Zhao, L.; Lee, V.H.F.; Ng, M.K.; Yan, H.; Bijlsma, M.F. Molecular subtyping of cancer: Current status and moving toward clinical applications. Brief. Bioinform., 2019, 20(2), 572-584.
[http://dx.doi.org/10.1093/bib/bby026] [PMID: 29659698]